Abivax (AAVXF) Change in Accured Expenses (2024 - 2026)

Abivax has reported Change in Accured Expenses for 3 years, with the latest figure at $7.7 million in Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 553.85% year-over-year to $7.7 million in Q1 2026; TTM through Mar 2026 was $2.5 billion, a 255.06% increase from a year earlier, with the FY2025 full-year figure at $2.5 billion, up 254.57% from the prior year.
• Change in Accured Expenses was $7.7 million for Q1 2026 at Abivax, down from $2.5 billion in the prior quarter.
• The five-year high for Change in Accured Expenses was $2.5 billion in Q4 2025, with the low at -$1.6 billion in Q4 2024.
• Average Change in Accured Expenses over 3 years is $97.2 million, with a median of $332796.1 recorded in 2025.
• The sharpest annual moves came in 2025 and 2026: Change in Accured Expenses tumbled 170.31% in 2025, then jumped 553.85% in 2026.
• Over 3 years, Change in Accured Expenses stood at -$1.6 billion in 2024, then jumped by 254.38% to $2.5 billion in 2025, then tumbled by 99.69% to $7.7 million in 2026.
• The last three Change in Accured Expenses figures came in at $7.7 million (Q1 2026), $2.5 billion (Q4 2025), and $5.5 million (Q3 2025), per Business Quant data.